Long-term data on CodeBreaK 100 sotorasib study presented at AACR

New data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, showing that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life.

The data were presented Dr Grace Dy, who led the study at Roswell Park Comprehensive Cancer Center, the longest-term data available from the multicenter CodeBreaK100 clinical trial in a plenary presentation.

Sotorasib, developed by US biotech giant Amgen (Nasdaq: AMGN) and marketed as Lumakras, is a targeted anticancer therapy granted accelerated Food and Drug Administration approval in May 2021 for treatment for adult patients with NSCLC whose tumors have a specific genetic alteration - G12C mutation of the KRAS gene - and whose tumors worsened and/or persisted despite earlier treatment. This orally administered drug is the first approved targeted therapy for any KRAS-mutated malignancy. KRAS G12C mutations represent about 13% of mutations in non-small cell lung cancers. Amgen sponsored the Rosewell Park study.